DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for splenic disease — screening already-approved drugs against its 28-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSplenic disease maps to a 28-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for splenic disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
amyloid P component, serum (APCS) — APCS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet n7pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4AVS · 1.399 Å · ligand 1-ACETYL-L-PROLINE (N7P). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1990 · 1 citations
Disorders of the Spleen: Pathophysiology and Management
AbstractThis beautifully illustrated, wellindexed 450 + -page volume presents a clear and comprehensive, yet concise, review of splenic disorders in adults and children. It begins with a discussion of normal anatomy and function, then proceeds to a review of gross and microscopic pathology in a variety of splenic disease states. Disturbed splenic function— both hyposplenism and hypersplenism—is discussed in depth. Emphasis is placed on pathophysiologic mechanisms, where known, and available clinical methods (including imaging techniques) for diagnosing the functional state of the spleen. There is detailed attention given to the workup and management of the patient with splenomegaly. Systematic review of neoplastic, storage/metabolic, infectious, and immune disorders is presented. Recommendations for treatment of asplenic individuals are included. This monograph is commended particularly for successfully relating data from the basic sciences to clinical features of disturbed splenic function. The pathology and relevant basic immunology are included not as a comprehensive review, but
Pacific Medical Journal · 2025 · 0 citations · open access
Diagnostic challenges of splenic disease: A clinical case description
AbstractThe scientific article presents a clinical case involving a diagnostic search related to splenic disease. The patient underwent a comprehensive examination and consultations with various specialists. As a result, a benign nature of the lesion in the unpaired parenchymal organ was established, and a follow-up management strategy was adopted, involving observation over the course of one year, followed by re-evaluation and a final decision on further management. The article analyzes data from current domestic and international literature sources concerning splenic pathology. The authors identified key features, emphasized the complexity of diagnosing splenic diseases, and highlighted the importance of histological examination of the affected organ to ensure an accurate final diagnosis
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
